Abstract
To present an intracavitary rotating shield brachytherapy (RSBT) delivery system for cervical cancer that is optimized for use with the 169Yb radioisotope. The system is compatible with existing clinical afterloaders and has the potential to deliver tumor-conformal dose distributions with high-risk clinical target volume (HR-CTV) D90-values equivalent to those of combined intracavitary-interstitial (IC/IS) HDR brachytherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
